Fisher & Paykel Healthcare's VP of Sales & Marketing Justin Callahan Purchases 142 Shares Through Employee Stock Purchase Plan

Details of Justin Callahan’s Share Acquisition via Employee Stock Purchase Plan

According to the NZX filing dated 2 July 2026, Justin Peter Callahan participated in a transaction on 1 July 2026 through Fisher & Paykel Healthcare’s Employee Stock Purchase Plan. This plan enabled him, as a senior manager, to purchase 142 ordinary shares at NZD $33.1882 per share. The acquisition followed an accepted offer to participate in the plan, which is available to eligible employees.

Employee Stock Purchase Plans like this are common among listed companies to align senior leadership’s financial interests with shareholders. By allowing employees to acquire shares at predetermined or market-related prices, these plans encourage long-term commitment and promote a proprietary interest in company performance. The disclosure complied with New Zealand’s Financial Markets Conduct Act 2013, requiring senior managers to report changes in their relevant interests promptly.

Callahan’s Updated Shareholding in Fisher & Paykel Healthcare

Before the 1 July 2026 purchase, Callahan held 220,867 ordinary shares beneficially. The acquisition of 142 shares increased his holding to 221,009 shares, all registered in his name. The 142-share increase represents approximately a 0.06% rise, reflecting a routine plan-based purchase rather than a significant open-market transaction. Nonetheless, ongoing accumulation through such plans may indicate management’s confidence in the company’s prospects.

Transaction Price of NZD $33.1882 Per Share

Callahan paid NZD $33.1882 per share for the 142 shares, totaling about NZD $4,712.72. This price reflects the terms of the Employee Stock Purchase Plan rather than an immediate market price at the time of purchase. The disclosure did not specify whether any discount was applied. Investors interested in the plan’s pricing details should consult the company’s employee share plan documentation or prior disclosures.

Role of Justin Callahan as Vice President of Sales & Marketing

Justin Peter Callahan serves as Vice President of Sales & Marketing at Fisher & Paykel Healthcare Corporation Limited. As a senior manager under the Financial Markets Conduct Act 2013, he must disclose changes to his financial interests in the company. In his role, Callahan oversees revenue generation and market development across the company’s global operations. Fisher & Paykel Healthcare, headquartered in New Zealand and dual-listed on the NZX and ASX, specializes in respiratory and acute care medical devices. Callahan’s participation in the Employee Stock Purchase Plan signals his ongoing personal investment in the company’s growth.

Broader Equity Interests: Options and Performance Share Rights

In addition to his direct shareholding, Callahan holds 103,960 options to acquire ordinary shares and 64,091 performance share rights, all beneficially owned and registered in his name. These equity-linked instruments provide further exposure to the company’s share price performance. While the disclosure did not detail vesting conditions or exercise prices, these holdings represent significant potential future equity interests, reinforcing Callahan’s alignment with Fisher & Paykel Healthcare’s long-term value creation.

Disclosure Timing and Compliance with Financial Markets Conduct Act 2013

The disclosure was lodged on 2 July 2026, one day after the share purchase on 1 July 2026, consistent with the prompt reporting requirements under sections 297(2) and 298(2) of New Zealand’s Financial Markets Conduct Act 2013. Callahan’s previous disclosure was dated 2 April 2026, making this the first update to his relevant interests in approximately three months. The disclosure was certified and signed by Raelene Leonard, General Counsel and Company Secretary, on Callahan’s behalf, ensuring accuracy and compliance.

Employee Stock Purchase Plan as a Retention and Alignment Strategy

The Fisher & Paykel Healthcare Employee Stock Purchase Plan is a structured equity participation program for eligible employees. Such plans are widely used by multinational listed companies to facilitate employee share ownership, often on favorable terms compared to open-market purchases. Callahan’s acceptance of the offer to participate indicates a planned acquisition cycle rather than a discretionary market purchase. Investor relations professionals typically view active management participation in these plans positively, as it aligns management’s financial interests with shareholders. The company did not disclose broader participation rates or plan terms in this update.

Market Impact and Context for Fisher & Paykel Healthcare Shares

This insider purchase disclosure is unlikely to have had an immediate material impact on Fisher & Paykel Healthcare’s share price. Small, plan-based acquisitions by senior managers typically do not drive significant market movements unless part of a larger insider trading trend. FPH, a major healthcare company listed on the ASX and NZX, experiences share price fluctuations mainly due to earnings results, product developments, regulatory news, and macroeconomic factors affecting global healthcare spending. Investors may consider this insider disclosure as one factor among many in evaluating management sentiment.

Investor Considerations Following This Disclosure

This disclosure provides investors with a routine update on the equity interests of a key senior executive. Future developments to watch include additional insider disclosures from other executives, updates to financial guidance, and forthcoming reporting periods that reveal revenue and earnings performance. Investors may also monitor changes to Callahan’s options and performance share rights, as vesting or exercises could materially affect his equity position. The company did not provide forward-looking operational or strategic guidance in this disclosure. For a comprehensive view of Fisher & Paykel Healthcare’s outlook, investors should refer to recent financial results, investor presentations, and official communications filed with the NZX and ASX.